| Recruiting | A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Dail Lipidemia, Type 2 Diabetes (T2DM), Metabolic Syndrome (MetS) | Phase 3 | 2025-12-11 |
| Recruiting | Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers Antioxidant Absorption | Phase 2 | 2025-09-09 |
| Recruiting | Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels Dyslipidemias | Phase 2 | 2024-12-02 |
| Completed | A Study to Evaluate Drug-Drug Interactions of Obicetrapib Tablets and Ezetimibe Tablets in Healthy Adult Subje Healthy Volunteers | Phase 1 | 2024-10-01 |
| Active Not Recruiting | A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque Lipidemia, Coronary Artery Disease, Plaque, Atherosclerotic | Phase 3 | 2024-05-16 |
| Completed | Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies Dyslipidemias, Hypercholesterolemia, Familial Hypercholesterolemia | Phase 3 | 2024-03-01 |
| Completed | Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib Healthy Volunteers | Phase 1 | 2024-02-05 |
| Completed | Investigating the Effect of Food on the Bioavailability of a Fixed Dose Combination of Obicetrapib and Ezetimi Healthy Volunteer Study | Phase 1 | 2024-01-20 |
| Active Not Recruiting | Investigating the Effect of Obicetrapib on Lipoprotein Metabolism Lipid Metabolism | Phase 1 | 2023-12-01 |
| Completed | PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic F Hepatic Impairment, Healthy | Phase 1 | 2023-11-30 |
| Completed | A Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and Rosuvastatin Healthy Volunteers | Phase 1 | 2023-11-11 |
| Completed | Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies Dyslipidemias, High Cholesterol, Hypercholesterolemia | Phase 3 | 2022-07-25 |
| Completed | A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Dyslipidemia, Hypercholesterolemia, High Cholesterol | Phase 2 | 2022-06-27 |
| Completed | Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy Dyslipidemias, High Cholesterol, Hypercholesterolemia | Phase 2 | 2022-03-09 |
| Active Not Recruiting | Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease Atherosclerotic Cardiovascular Disease | Phase 3 | 2022-02-07 |
| Completed | Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease Early Alzheimer's Disease | Phase 2 | 2022-01-12 |
| Completed | Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies Dyslipidemias, High Cholesterol, Hypercholesterolemia | Phase 3 | 2021-12-15 |
| Completed | Randomized Study of Obicetrapib in Combination With Ezetimibe Dyslipidemias, High Cholesterol, Hypercholesterolemia | Phase 2 | 2021-02-23 |
| Completed | Randomized Study of Obicetrapib as an Adjunct to Statin Therapy Dyslipidemias, High Cholesterol, Hypercholesterolemia | Phase 2 | 2021-02-18 |